Skip to main content
Figure 5 | Journal of Translational Medicine

Figure 5

From: Favorable in vitro effects of combined IL-12 and IL-18 treatment on NK cell cytotoxicity and CD25 receptor expression in metastatic melanoma patients

Figure 5

The effect of cytokines on CD158a and CD158b receptor expression on NK cell subsets. a) The percentage and mean fluorescence intensity (MFI) of CD158a KIR receptor do not change significantly (p > 0.05, Wilcoxon signed rank test) on CD3CD56+ NK cells and their CD3CD56dim+ and CD3CD56bright+ subsets in healthy controls (HC) and metastatic melanoma (MM) patients after 18 h in vitro treatments of peripheral blood mononuclear cells (PBMC) with IL-12 or IL-18, alone, or with their combination; b) Contrary to the expression in percentage, MFI of the other inhibitory KIR, CD158b, decreases significantly (*p < 0.05, Wilcoxon signed rank test) on NK cells and the dim subset in both healthy controls (HC) and metastatic melanoma (MM) patients after 18 h in vitro treatment with IL-12 and IL-18 in combination. All results are obtained by Flow cytometry and are expressed as mean ± SE for 18 HC and 27 MM patients.

Back to article page